Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss

Executive Summary

Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.

You may also be interested in...



In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?

Regulatory and financial incentives have sparked major investment in orphan drug development, but now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?

In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?

Regulatory and financial incentives have sparked major investment in orphan drug development. One-third of the new molecular entities and novel biologics approved by FDA in the past five years have been orphan drugs. But now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?

Cancer Checkpoint Race Takes Turn With BMS’ New Lung Trial, Merck’s Rolling Melanoma BLA

Bristol-Myers Squibb’s launch of a new Phase III lung cancer study of nivolumab monotherapy in those with high expression of PD-L1 lung cancer patients raises questions about the role of the biomarker and the possibility of combination therapy with Yervoy. The PD-L1 biomarker is still being evaluated and strategies are likely to differ depending on drug and tumor type.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel